Core Insights - Akoya Biosciences has announced a collaboration with the Singapore Translational Cancer Consortium (STCC) for the SUPER study, which aims to identify and validate biomarkers predicting responses to immune checkpoint inhibitors [1][2][6] - The study will focus on a unique cohort of 200 patients, including 100 exceptional responders and 100 hyper-progressors, to uncover biological determinants of treatment outcomes [2][5] Study Objectives - Identify and validate the assay combination and biomarker profile that best predicts response or refractoriness to PD1/PDL1 inhibition [7] - Develop a combinatorial assay kit/model for predicting PD1/PDL1 treatment response for clinical applications [7] - Establish a national biomarker discovery program for extreme responders to cancer treatment [7] Collaboration Details - The SUPER study will utilize Akoya's IO60 panel for spatial proteomic analysis, enhancing biomarker-driven cancer treatment [1][5] - The collaboration aims to integrate spatial approaches with DNA/RNA sequencing to identify predictors of response to immunotherapy [5][6] - The study is a multi-institutional effort involving several key healthcare and research institutions in Singapore [6][10] Industry Impact - The findings from the SUPER study could significantly influence future cancer immunotherapy strategies and healthcare cost optimization [5][6] - By bridging spatial proteomics with clinical insights, the initiative has the potential to shape the future of precision oncology [6]